Merrill A. McPeak
Merrill A. McPeak's purchase track record
How the stock did after each of Merrill A. McPeak's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/20/2024 | IOVA | $2.29M | -14.2% | -6.2% | +12.5% |
| 9/18/2023 | IOVA | $56K | +32.4% | +136.6% | +15.6% |
| 12/21/2022 | IOVA | $62K | -2.0% | +36.2% | +12.6% |
| 11/28/2022 | IOVA | $125K | +20.5% | +48.7% | +6.1% |
| 5/31/2022 | IOVA | $136K | +54.8% | -9.0% | -4.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Iovance Biotherapeutics sees analyst target raise and whale activity. Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.
Transaction History
| RSSS | ▲ Buy | Option Exercise | 75,000 | $53K | 11/12/2025 | View on chart |
| RSSS | ▲ Buy | Option Exercise | 75,000 | $83K | 6/18/2025 | View on chart |
| RSSS | ▲ Buy | Option Exercise | 50,000 | $53K | 5/2/2025 | View on chart |
| IOVA | ▲ Buy | Open Market | 250,000 | $2.3M | 2/20/2024 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $56K | 9/18/2023 | View on chart |
| RSSS | ▲ Buy | Option Exercise | 50,000 | $57K | 1/16/2023 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $62K | 12/21/2022 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $63K | 11/29/2022 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $62K | 11/28/2022 | View on chart |
| IOVA | ▲ Buy | Option Exercise | 40,000 | $226K | 8/23/2022 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $68K | 5/31/2022 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $68K | 5/31/2022 | View on chart |
| RSSS | ▲ Buy | Option Exercise | 50,000 | $60K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
RSSS partners with Scite and MDPI to enhance AI research tools
Research Solutions has partnered with Scite and MDPI to integrate open‑access research into its AI platforms. The collaboration is intended to make scholarly content more discoverable, attributed and measurable for users. The news arrives while the stock is near its $2.20 support level, a price point that has been tested frequently.
RSSS partners with Scite and MDPI to enhance AI research tools. Research Solutions has partnered with Scite and MDPI to integrate open‑access research into its AI platforms. The collaboration is intended to make scholarly content more discoverable, attributed and measurable for users. The news arrives while the stock is near its $2.20 support level, a price point that has been tested frequently.